1. www.adcsummit.com
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUP DISCOUNTS AVAILABLE
A: ADC payloads: Availability and
mechanisms of action
Workshop Leaders:
David Thurston, Professor of Drug Discovery, King’s College London
Paul Jackson, Project Manager, Femtogenix
08.30 – 12.30
B: Developments in high potency
API manufacturing
Workshop Leaders:
Richard Denk, Head Sales Containment, SKAN AG
Martin Glaettlim, Sales Engineering Containment, SKAN AG
13.30 – 17.30
PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS
Wednesday 25th May 2016, Holiday Inn Kensington Forum, London, UK
REGISTER BY 29TH FEBRUARY AND RECEIVE A £400 DISCOUNT
REGISTER BY 31ST MARCH AND RECEIVE A £200 DISCOUNT
@SMIPHARM
#SMiADC
SMi Present the 5th Annual Conference on…
ADC Summit
Holiday Inn Kensington Forum, London, UK
23 - 24
MAY
2016
Exploring the latest innovations in conjugation approaches and
technologies for the development of next generation ADCs
Highlights for 2016:
• Takeda presents how ADCETRIS® (brentuximab vedotin)
developed to treat Hodgkin Lymphoma
• Advancement in ADCs:
A step closer to magic bullets in war against cancer
• Safety at the forefront - homogeneity of ADCs for highly
effective and safer cancer therapy
Sponsored by
Chairs for 2016:
Rakesh Dixit,
Vice President, R & D,
MedImmune
Mahendra Deonarain,
Chief Science Officer,
Antikor Biopharma Ltd
Featured Speakers:
• Ashish Gautam, Global Medical Lead – ADCETRIS, Takeda
• Ben-Fillippo Krippendorff, Principal Scientist, Roche
• Jeremy Parker, Principal Scientist, Pharmaceutical
Development, AstraZeneca
• Debbie Meyer, Senior Principal Scientist, Pfizer
• Jens Lohrmann, Senior Global Program Manager, Novartis

2. ADC Summit
Day One | Monday 23rd May 2016 www.adcs
Register online at: www.adcsummit.com • Alternatively fax yo
Sponsored by
08.30 Registration and Coffee
09.00 Chairman’s opening remarks
Rakesh Dixit, Vice President, R & D, MedImmune
OPENING ADDRESS
09.10 Advancement in antibody drug conjugates: A step closer to
magic bullets in war against cancer
• The 5 Rs of ADCs: the right target, the right linker, the right
warhead, the right antibody, the right site of conjugation
• Recent developments with site-specific conjugation
improving the therapeutic index of ADCs
• Exploring how reducing hydrophobicity of homogeneous
ADCs can improve therapeutic index
• Discussing how the stability of the linker can improve
therapeutic index
• Discussing the on- and off-target toxicity issues
• Clinical development of ADCs
Rakesh Dixit, Vice President, R D, MedImmune
INNOVATIONS IN ADC
09.50 Warheads for targeted therapies of cancer: Strategies for
designing and efficient synthesis of DNA cross-linkers
• Some DNA cross-linkers are too toxic to be used as
antineoplastic agents; instead, they are excellent
candidates for the design of ligand-drug conjugates for
cancer targeting
• New concept for design of DNA cross-linkers
• Efficient total synthesis of cross-linker derivatives for
conjugation
Iontcho Vlahov, VP Discovery Chemistry, Endocyte, Inc.
10.30 Morning Coffee
11.00 Development of best-in-class, homogeneous ADCs for highly
effective and safer cancer therapy
• Sortase-mediated antibody conjugation (SMAC™): A robust
and efficient means to attach toxic payloads to antibodies
• Highly site-specific conjugation yields homogenous drug
product with defined efficacy, PK properties and safety
profile
• Peptide-based linker structure circumvents IP issues and
provides superior serum stability
• In vivo data on lead ADCs generated using site-specific
SMAC™ - technology will be presented
Roger R. Beerli, Chief Scientific Officer, NBE-Therapeutics Ltd.
11.40 Preclinical efficacy of a novel anti-C4.4a (LYPD3) antibody
drug conjugate BAY 1129980 for the treatment of lung cancer
• C4.4a (LYPD3) is a novel targeting antigen overexpressed in
several cancer indications
• Design of BAY 1129980 employing a novel auristatin
• Discuss the in vitro and in vivo efficacy profile
• Phase 1 clinical studies updates (NCT02134197)
Joerg Willuda, Senior Scientist, Bayer
12.20 Networking Lunch
13.50 Producing better ADCs using ThioBridge™ conjugation
• Disulfide re-bridging conjugation to reduce ADC
heterogeneity
• ThioBridge™ linkers provide stable conjugation
• PK profiles of ThioBridge™ ADCs vs maleimide conjugation
• Development of more efficacious ADCs
George Badescu, Director of Scientific Affairs, Abzena
14.30 Novel site-specific conjugation tools
• N-terminal serine modification for antibody conjugation:
SeriMabs
• Excellent in vitro activity achieved through site-specific
conjugation
• Site-specific conjugates are stable and efficacious in vivo
Thomas A. Keating, Director, Biochemistry, ImmunoGen, Inc.
15.10 Afternoon Tea
NOVEL ADC TECHNOLOGIES
15.50 A Novel FRET reagent reveals the intracellular processing of
antibody-drug conjugates
• Our FRET assay provides a facile and robust assessment of
intracellular ADC activation
• The antigen-mediated antibody internalization is determined
by the nature of cell, not by the nature of antigen
• A certain tumor cell showed a limited cytosolic transport of
the payload despite the efficient linker cleavage
Byoung-Chul Lee, Scientist, Protein Chemistry, Genentech
16.20 Expanding the scope of ADC targets through novel
conjugation technologies
• APN linkers with increased serum stability
• New generation of DM1- and MMAE-based payloads
• Expanding the scope of ADC targets by fine-tuning the drug
release mechanism
Oleksandr (Sasha) Koniev, CEO Founder, Syndivia
17.00 Platform technologies for homogeneous and versatile protein
modification
• Functional disulfide re-bridging
• Controlled dual “click” functionalisation
• Site-selective antibody conjugation
• Photodynamic therapy
• Reversible and irreversible cysteine modification
Vijay Chudasama, Lecturer Organic Chemistry and Chemical
Biology, University College London
17.40 Chairman’s Closing Remarks and Close of Day One
Rakesh Dixit, Vice President, R D, MedImmune
Abzena offers a suite of complementary services and technologies.
Its range of technologies include immunogenicity assessment,
antibody drug conjugation, protein engineering, PEGylation, cell
line development, GMP manufacturing and a range of bespoke
assays to enables the development of better biopharmaceuticals
which will have a greater chance of reaching the market.
www.abzena.com
Sponsorship and Exhibition Opportunities
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your
company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base
within the context of an independent discussion specific to your industry.
Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
Official Media Partners

3. ADC Summit
Day Two | Tuesday 24th May 2016summit.com
08.30 Registration and Coffee
09.00 Chairman’s opening remarks
Mahendra Deonarain, Chief Science Officer, Antikor Biopharma Ltd
LEARNING FROM KADCYLA AND ADCETRIS
OPENING ADDRESS / KEYNOTE ADDRESS
09.10 ADCETRIS® (brentuximab vedotin) developed to treat
Hodgkin Lymphoma
• Development of ADCETRIS® - Takeda and Seattle Genetics
alliance
• Exploring the mechanism pathway of ADCETRIS®
• Data published to date from ADCETRIS® registration studies
• Ongoing ADCETRIS® clinical development
Ashish Gautam, Global Medical Lead - ADCETRIS, Takeda
09.50 Predicting tissue distribution and clearance of antibody
formats to improve selectivity of targeted therapies
• Estimating the tissue distribution of antibodies and antibody
fragments based on plasma pharmacokinetics
• Estimation of ADC distribution and tissue specific clearances
that influence the therapeutic window
• Optimise biotherapeutic modalities with optimal
biodistribution properties to target (and avoid) specific tissues
Ben-Fillippo Krippendorff, Principal Scientist, Roche
10.30 Morning Coffee
CHALLENGES AND LESSONS LEARNT
11.00 Impact of drug loading on ADC target binding and cytotoxicity
• Demonstrating the impact of different levels of drug loading
• ADC target binding and cytotoxicity
• Case studies
Debbie Meyer, Senior Principal Scientist, Pfizer
11.40 Targeting Cadherin-6 (CDH6) with a novel ADC for the
treatment of ovarian and renal cancers
• ADC lead selection covering optimal choice of antibody
and linker/payload
• PK/PD studies to evaluate MoA and projected efficacious
dose
• Population-scale in vivo assessment in ovarian cancer PTX
clinical trial
Carl Uli Bialucha, Senior Investigator,
Novartis Institutes For Biomedical Research
12.20 Networking Lunch
13.50 Engineering and development of novel immunotargeted
nanotherapeutics
• Engineering considerations for a novel antibody directed
nanotherapeutic
• Target expression and demonstration of targeting
• Preclinical demonstration of activity and altered tox profile
• Diagnostic development and clinical trial design for
upcoming Phase I
Daryl Drummond, Senior Director, Nanotherapeutics,
Merrimack Pharmaceuticals Inc
14.30 The design, synthesis and scale-up of an ADC tubulysin
payload
• Development of novel ADC payloads based on Tubulysins
• Identification and development of synthetic routes
• Scale up of chemistry to deliver material for toxicology and
clinical studies
Jeremy Parker, Principal Scientist, Pharmaceutical
Development, AstraZeneca
15.10 Afternoon Tea
15.50 Challenges and lessons learnt in ADC CMC development and
outsourcing
• Buy vs. make: Considerations and critical success factors
• Scale-up and site transfer of a conjugation process with
impact on key product quality attributes: case studies
• Analytical transfers: considerations and lessons learned from
a challenging assay transfers
Jens Lohrmann, Senior Global Program Manager, Novartis
16.20 Fragment drug conjugates (FDCs): A unique drug class or just
smaller ADCs?
• Using optimised single chain Fvs to obtain high
drug-to-antibody ratio (DAR)
• Impact of drug/linker structure on FDC properties
• Dosing, PK and penetration issues
Mahendra Deonarain, Chief Science Officer, Antikor Biopharma Ltd
17.00 Chairman’s Closing Remarks and Close of Day Two
Mahendra Deonarain, Chief Science Officer, Antikor Biopharma Ltd
our registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
Want to know how you can get involved? Interested in promoting your services to this market?
Contact Honey De Gracia, SMi Marketing on +44 (0) 207 827 6102 or email: hdegracia@smi-online.co.uk
Supported by

4. A: ADC payloads: Availability
and mechanisms of action
Workshop Leaders:
David Thurston, Professor of Drug Discovery,
King’s College London
Paul Jackson, Project Manager, Femtogenix
HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 25th May 2016
08.30 – 12.30
Holiday Inn Kensington Forum, London, UK
Overview of workshop
This workshop will focus on the variety of chemical and
biological payloads available for attaching to antibodies,
and those in the discovery and/or development
phase. Discussion will be based on how the structure
and mechanism of action of payloads can affect
their toxicities and clinical activities when attached to
antibodies, and how the best payload can be identified
for a particular cancer type and/or antibody.
Programme
08.30 Registration
09.00 Mechanisms of actions
• The range of payload types commercially
available and their mechanism of actions
• Payloads at the discovery or development
stages
10.00 Molecular modelling technique
• Molecular modeling approaches to
payload discovery
• Designing maximum cytotoxicity into
payloads
11.00 Morning Coffee
11.30 Design and engineering of payloads
• Engineering payloads to not release
prematurely
• Strategies to minimise the hydrophobicity
• Ensuring maximum resistance to
P-glycoprotein pumps in payload design
12.30 End of Workshop A
About the workshop leaders:
David Thurston is a Professor of Drug Discovery in the
Institute of Pharmaceutical Science at King’s College
London. He has a first degree in pharmacy and a PhD
in synthetic medicinal chemistry. David is one of the
scientific co-founders of Spirogen Ltd (recently acquired
by AstraZeneca), and acted as CSO for the company
fromitsformationin2000until2011. Heisalsoaco-founder
of Transcriptogen Ltd, which focusses on the discovery
and development of small-molecule transcription factor
inhibitors as oncology agents, and Femtogenix Ltd which
is involved with the discovery of novel DNA Minor Groove
Binding Agents (MGBAs) with potential application as
ADC payloads. David has published widely in medicinal
chemistry/chemistry journals, is author of the textbook
“Chemistry and Pharmacology of Anticancer Drugs”,
and Editor-in-Chief of the Drug Discovery book series of
the Royal Society of Chemistry.
Dr. Jackson holds an undergraduate degree in
the pharmaceutical sciences (LJMU), an MSc in
Bioinformatics (University of Liverpool) and a PhD in
Computational Drug Discovery (King’s College London).
Hehasextensiveexperienceininsilicomethods,including
structure-, ligand- and fragment-based drug design. He
has also been involved in the development of QSAR,
lead optimization and molecular docking techniques.
Both his PhD and post-doctoral research have involved
the development of novel computational chemistry
methods (e.g., molecular dynamics simulation
techniques) for the design and evaluation of ADC
payloads, which has contributed to Femtogenix’s novel
payload discovery platform.

5. B: Developments in high potency
API manufacturing
Workshop Leaders:
Richard Denk, Head Sales Containment, SKAN AG
Martin Glaettlim, Sales Engineering Containment,
SKAN AG
HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 25th May 2016
13.30 – 17.30
Holiday Inn Kensington Forum, London, UK
Overview of workshop
ADC payloads typically present high toxicity at extremely
low doses when unconjugated, resulting in very low
Occupational Exposure Levels (OEL). Their production
requires chemistry carried out at small scale under high
containment in a GMP compliant environment. For
these reasons, any activity related to ADC payloads
production requires a contained and specially designed
environment, including those for RD, analytical,
production, storage.
Programme
13.30 Registration
14.00 What does containment mean for very low
OEL’s
• Containment in low nanogram levels
requires a new approach how to design the
containment and the process
• What technologies are on the market
• How to design the containment for the
API production as well as for the aseptic
processing
16.00 Afternoon Tea
16.30 Case study on a low OEL aseptic processing
solution
• Important considerations and parameters
during design of low OEL aseptic processing
• How to combine EHS and GMP
• Final design implementation
17.30 End of Workshop B
About the workshop leaders:
Richard Denk, Head Sales Containment, SKAN AG
Richard Denk has studied mechanical engineering and
is working at the company SKAN AG, headquartered
in Allschwil in the position of Head Containment Group.
Mr. Denk founded 8 years ago the expert Containment
group of the ISPE D / A / CH. The Containment Group
published the Containment Manual in September 2015.
The Containment Manual does provide a full overview
on Containment. Furthermore, Mr. Denk has spent nearly
20 years with the subject production of highly active /
highly hazardous substances and has developed the
containment pyramid.
Martin Glättli is the Sales Engineer for containment at
SKAN AG in Switzerland. He is a frequent speaker at
industry events, and writes articles for pharmaceutical
engineering journals on a regular basis.For over 10 years
Martin has acquired in-depth knowledge of environment-
protected process design and realized state-of-the-art
solutions for various well-known companies. His current
work focuses on offering solutions for cleaning and
maintenance-friendly containment design, as well as
closing the gap between the requirements of contained
processing and sterile processing technology.

6. Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferencesdocumentationviatheDocumentPortaltoanydelegatewhohaspaidbutisunable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able
to provide documentation in these circumstances. We cannot accept cancellations of orders
placed for Documentation or the Document Portal as these are reproduced specifically to order.
If we have to cancel the event for any reason, then we will make a full refund immediately, but
disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about
other products and services. Unless you tick here □ we may also share your data with third parties
offeringcomplementaryproductsorservices.Ifyouhaveanyqueriesorwanttoupdateanyofthe
data that we hold then please contact our Database Manager databasemanager@smi-online.
co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your
address on the attached letter.
Payment must be made to SMi Group Ltd, and received before the event, by one of the
following methods quoting reference P-172 and the delegate’s name. Bookings made within
7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here.
______________________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
□ Book by 29th February 2016 to receive £400 off the conference price
□ Book by 31st March 2016 to receive £200 off the conference price
EARLY BIRD
DISCOUNT
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference 2 Workshops £2697.00 + VAT £3236.40
□ Conference 1 Workshop A □ B □ £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ 2 Workshops £1198.00 + VAT £1437.60
□ 1 Workshop only £599.00 + VAT £718.80
Workshop A □ Workshop B □
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712
I cannot attend but would like to purchase access to the following
Document Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
Unique Reference Number
Our Reference LVP-172
DELEGATE DETAILS
Terms and Conditions of Booking
PAYMENT
VAT
CONFERENCE PRICES
DOCUMENTATION
VENUE Holiday Inn Kensington Forum, 97 Cromwell Rd, London SW7 4DN, UK
5th ANNUAL ADC SUMMIT
Conference: Monday 23rd Tuesday 24th May 2016, Holiday Inn Kensington Forum, London, UK Workshops: Wednesday 25th May 2016, London, UK
4 WAYS TO REGISTER
www.adcsummit.com
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK